Alexis Borisy - Foundation Medicine Chairman of the Board, Co-Founder
Chairman
Dr. Alexis Borisy is redesignated as Director of the Company effective February 6, 2017. He was Chairman of the Board, CoFounder of Foundation Medicine, Inc. He cofounded Foundation Medicine in 2009 and served as our interim Chief Executive Officer through May 2011. Since 2010, Mr. Borisy was a partner at Third Rock Ventures, a life sciences VC firm focused on the formation, development and strategy of new companies. He cofounded Blueprint Medicines Corporationration in 2011 and served as its interim chief executive officer, and currently is on its board of directors. In addition, since July 2013 Mr. Borisy has served as chairman of Warp Drive Bio, LLC, a life sciences company focusing on genomics where he served as chief executive officer from 2011 to July 2013. Mr. Borisy also serves on the board of directors of Editas Medicine and Revolution Medicines, Inc. From 2007 through 2012, Mr. Borisy served as chairman of FORMA Therapeutics, Inc., a life science company focused on targeting cancers for treatment. In 2000, Mr. Borisy founded CombinatoRx, Inc., a drug development company, and served as its chief executive officer and on its board of directors from 2000 to 2009. Mr. Borisy holds an A.B. in chemistry from the University of Chicago, and an A.M. from Harvard University. since 2017.
| Age | 45 |
| Tenure | 7 years |
| Phone | 617 418-2200 |
| Web | www.foundationmedicine.com |
Foundation Medicine Management Efficiency
Foundation Medicine's management efficiency ratios could be used to measure how well Foundation Medicine manages its routine affairs as well as how well it operates its assets and liabilities.The company has 90 M in debt with debt to equity (D/E) ratio of 476.2, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Foundation Medicine has a current ratio of 2.22, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Foundation Medicine until it has trouble settling it off, either with new capital or with free cash flow. So, Foundation Medicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Foundation Medicine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Foundation to invest in growth at high rates of return. When we think about Foundation Medicine's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 5 records | CHAIRMAN Age | ||
| Robert Sands | Constellation Brands Class | 61 | |
| Sigurd Thorvildsen | Awilco Drilling PLC | 50 | |
| Robert Gamgort | Keurig Dr Pepper | 62 | |
| Yasutake Tango | Japan Tobacco ADR | 67 | |
| Richard Sands | Constellation Brands Class | 71 | |
Management Performance
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 |
Foundation Medicine Leadership Team
Elected by the shareholders, the Foundation Medicine's board of directors comprises two types of representatives: Foundation Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foundation. The board's role is to monitor Foundation Medicine's management team and ensure that shareholders' interests are well served. Foundation Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foundation Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Day, Director | ||
| Michael Varney, Director | ||
| Krishna Yeshwant, Independent Director | ||
| David Daly, Chief Commercial Officer | ||
| David Schenkein, Independent Director | ||
| Melanie Nallicheri, Chief business Officer and head of Biopharma | ||
| Alexis Borisy, Chairman of the Board, Co-Founder | ||
| Steven Kafka, Pres and COO | ||
| Evan Jones, Independent Director | ||
| Vincent Miller, Chief Medical Officer | ||
| Konstantin Fiedler, COO | ||
| Michael Pellini, President CEO, Director | ||
| Robert Hesslein, Senior Vice President General Counsel | ||
| Sandra Horning, Director | ||
| Michael Doherty, Head of Product Development | ||
| Jason Ryan, CFO | ||
| Michael Dougherty, Director | ||
| Tom Civik, Chief Commercial Officer | ||
| Troy Cox, CEO, Director | ||
| Thomas Civik, Chief Commercial Officer |
Foundation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Foundation Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 | |||
| Profit Margin | (0.0001) % | |||
| Operating Margin | (83.98) % | |||
| Current Valuation | 5.09 B | |||
| Shares Outstanding | 37.14 M | |||
| Shares Owned By Insiders | 58.74 % | |||
| Shares Owned By Institutions | 36.24 % | |||
| Number Of Shares Shorted | 2.35 M | |||
| Price To Earning | (9.70) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Foundation Stock
If you are still planning to invest in Foundation Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Foundation Medicine's history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |